✨ Wrapping up an inspiring week at @adpdnet in beautiful Vienna! 🧠🇦🇹
An incredible opportunity to dive into the latest advances in neurodegeneration, share ideas, and connect with a vibrant international community of researchers and clinicians 🤝🌍
6/ Bottom line:
Autonomic testing is feasible and should be part of the DLB diagnostic toolkit! Understanding these physiological changes can improve both diagnosis & quality of life for patients.
What do you think? Let’s discuss! 👇#MedTwitter#NeuroTwitter
One week later, but beyond happy to share that our study on Autonomic Dysfunction in Dementia with Lewy Bodies is finally out on THE @GreenJournal!
⬇️⬇️⬇️
https://t.co/ZSsM7yIE8y
Check this thread!
2/ We also looked to differences according to presence/absence of nigrostriatal denervation: patients with normal DaT-SPECT have worse peripheral autonomic responses than those with pathologic DaT-SPECT! This supports different patterns of alpha-synuclein spreading in DLB 🧠!
#PubMed being down is a disaster for science and medicine. It's an essential resource for accessing scientific papers and staying up-to-date. It's like the canary in the coal mine for researchers – a sign that something bigger is off. 🦜⚠️
Two competing definitions of #Alzheimer’s are being proposed. One sees anyone with amyloid in the brain as having the disease, and one requires objective cognitive deficits. While it may seem like a semantic argument, the implications are immense. #ENDALZ
https://t.co/GgDP1lMpxB
How should European clinicians deal with Lecanemab's rejection by the EMA?
Standardized reporting on its ongoing real-world use might persuade specialists about the drug’s effectiveness and safety
#Alzheimers#Lecanemab#EMA
Read more! ⬇️⬇️⬇️
https://t.co/7wmvOj1Lzb
Blessed with the luck of casually being at the 4th 💧CSF Society in Barcelona the second the new criteria for AD drop 👀(➡️check here: https://t.co/AkTmxPwNu5). Great chance to discuss them with great minds!
New online! Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease https://t.co/qjEnqezksU